Maravai LifeSciences Holdings financials
$7.65+0.26%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $185.7M | $259.2M | $288.9M | $883.0M | $799.2M | $284.1M |
| Gross profit | $34.0M | $108.3M | $140.2M | $714.0M | $658.7M | $204.4M |
| Gross margin | 18.3% | 41.8% | 48.5% | 80.9% | 82.4% | 72.0% |
| Operating income | -$215.3M | -$235.6M | -$31.6M | $574.2M | $543.4M | $100.9M |
| Net income | -$130.8M | -$144.8M | -$119.0M | $220.2M | $182.0M | $76.9M |
| Net margin | −70.4% | −55.9% | −41.2% | 24.9% | 22.8% | 27.1% |
| Diluted EPS | $-0.90 | $-1.05 | $-0.90 | $1.67 | $1.56 | $2.36 |
| EBITDA | -$77.2M | -$22.3M | $15.1M | $598.3M | $576.9M | $102.2M |
| Operating cash flow | -$57.6M | $7.5M | $126.2M | $536.0M | $368.6M | $152.2M |
| Free cash flow | -$70.7M | -$22.2M | $60.7M | $518.9M | $353.7M | $126.8M |
| Diluted shares | 144.4M | 137.9M | 131.9M | 255.3M | 257.8M | 28.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $216.9M | $322.4M | $575.0M | $632.1M | $551.3M | $236.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $321.9M | $327.0M | $556.7M | $527.4M | $530.6M | $590.8M |
| Total assets | $770.6M | $1.01B | $1.49B | $2.28B | $1.92B | $1.27B |
| Total liabilities | $397.9M | $431.0M | $697.6M | $1.38B | $1.37B | $1.12B |
| Shareholders' equity | $372.7M | $577.2M | $789.9M | $905.2M | $545.4M | $154.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology